Differential Responses to Targeted Therapies in Non-Small Cell Lung Cancer: A Comparative Analysis of Outcomes in...

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are a standard treatment for EGFR mutation-positive non-small cell lung cancer (NSCLC).
• The presence of concurrent gene alterations in EGFR-mutant NSCLC may impact treatment efficacy.
• Understanding these impacts is crucial for optimizing patient care and predicting treatment response.

Purpose of the Study:

• To evaluate the treatment outcomes of EGFR-mutant NSCLC patients with concurrent gene alterations.
• To determine the predictive significance of these concurrent alterations on response to EGFR-TKI therapy.

Main Methods:

• A retrospective cohort study was conducted using next-generation sequencing (NGS) data from January 2019 to June 2023.
• Patients were categorized into two groups: single EGFR mutation and concurrent EGFR mutations.
• Treatment responses and progression-free survival (PFS) were analyzed.

Main Results:

• The overall response rate (ORR) was 67% and disease control rate (DCR) was 82.6% in the study cohort.
• Progression-free survival (PFS) was significantly shorter in patients with concurrent EGFR mutations (11.00 months) compared to those with single EGFR mutations (15.03 months) (P = 0.001).
• Among concurrent mutations, ALK alterations showed the longest PFS (13.43 months), while MET alterations had the shortest PFS (4.77 months).

Conclusions:

• Concurrent gene alterations in EGFR-mutant NSCLC are associated with reduced efficacy of EGFR-TKIs.
• Patients with KRAS, BRAF, ROS1, or MET mutations exhibit poorer predictive outcomes when treated with EGFR-TKIs.
• These findings highlight the importance of comprehensive genomic profiling for predicting EGFR-TKI treatment response in NSCLC.